With their proven effectiveness and safety, GLP-1 receptor agonists (GLP-1 RAs) have become the leading weight-loss medications worldwide, prompting the pharmaceutical industry to ramp up research and development efforts in this area
Key Takeaway: Anxiety on semaglutide is often a secondary symptom caused by physical side effects like nausea or changes in how other medications are absorbed, rather than a direct psychological shift
A midstage study of the drug in celiac disease remains ongoing, with results expected in the second half of 2026, the company said
Safety, tolerability and weight reduction findings of oral amycretin: a novel amylin and glucagon-like peptide-1 receptor co-agonist, in a first-in-human study
[DOI] [PubMed] [Google Scholar] 272.Paixao C., Dias C.M., Jorge R., Carraca E.V., Yannakoulia M., de Zwaan M., Soini S., Hill J.O., Teixeira P.J., Santos I